These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
126 related items for PubMed ID: 10946807
21. Interleukin-13 genetic polymorphisms in Singapore Chinese children correlate with long-term outcome of minimal-change disease. Wei CL, Cheung W, Heng CK, Arty N, Chong SS, Lee BW, Puah KL, Yap HK. Nephrol Dial Transplant; 2005 Apr; 20(4):728-34. PubMed ID: 15728267 [Abstract] [Full Text] [Related]
22. Immunodynamics of minimal change nephrotic syndrome in adults T and B lymphocyte subsets and serum immunoglobulin levels. Yokoyama H, Kida H, Tani Y, Abe T, Tomosugi N, Koshino Y, Hattori N. Clin Exp Immunol; 1985 Sep; 61(3):601-7. PubMed ID: 3878244 [Abstract] [Full Text] [Related]
24. Nephrotic syndrome associated with diffuse mesangial hypercellularity: is it a heterogeneous disease entity? Joh K, Matsuyama N, Kanetsuna Y, Usui N, Hattori M, Yumura W, Aizawa S. Am J Nephrol; 1998 Sep; 18(3):214-20. PubMed ID: 9627037 [Abstract] [Full Text] [Related]
26. Long term study of mesangial proliferative glomerulonephritis with IgM deposits. Vangelista A, Frascá G, Biagini G, Bonomini V. Proc Eur Dial Transplant Assoc; 1981 Sep; 18():503-7. PubMed ID: 7329978 [Abstract] [Full Text] [Related]
27. Autoantibodies in minimal change nephrotic syndrome. Tina LU, Phillips TM, Calcagno PL. Int J Pediatr Nephrol; 1984 Jun; 5(2):63-6. PubMed ID: 6386721 [Abstract] [Full Text] [Related]
28. Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome. Ueda N, Takahashi K, Akioka Y, Morooka M, Ogawa A, Tsuzuki K. J Nephrol; 2009 Jun; 22(5):610-5. PubMed ID: 19809993 [Abstract] [Full Text] [Related]
29. Depression of normal lymphocyte transformation by sera of patients with minimal change nephropathy and other forms of nephrotic syndrome. Taube D, Chapman S, Brown Z, Williams DG. Clin Nephrol; 1981 Jun; 15(6):286-90. PubMed ID: 7249426 [Abstract] [Full Text] [Related]
30. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Peters HP, van de Kar NC, Wetzels JF. Neth J Med; 2008 Nov; 66(10):408-15. PubMed ID: 19011266 [Abstract] [Full Text] [Related]
36. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Li X, Li H, Chen J, He Q, Lv R, Lin W, Li Q, He X, Qu L, Suya W. Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091 [Abstract] [Full Text] [Related]
37. Immunopathologic study of minimal change glomerular disease with mesangial IgM deposits. Cavallo T, Johnson MP. Nephron; 1981 Jun; 27(6):281-4. PubMed ID: 7266716 [Abstract] [Full Text] [Related]
38. Chronic relapsing minimal change nephrotic syndrome with or without mesangial deposits: long term follow-up. Papadopoulou ZL, Jenis EH, Tina LU, Novello AC, Jose PA, Calcagno PL. Int J Pediatr Nephrol; 1982 Sep; 3(3):179-86. PubMed ID: 6754644 [No Abstract] [Full Text] [Related]
40. Pattern of steroid resistant nephrotic syndrome in children living in the kingdom of Saudi Arabia: a single center study. Kari JA, Halawani M, Mokhtar G, Jalalah SM, Anshasi W. Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):854-7. PubMed ID: 19736491 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]